Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

166.38 -0.18 (-0.11%)
Streaming Delayed Price Updated: 11:49 AM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
How Do Investors Really Feel About Natera?
 
Via Benzinga
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
From Natera, Inc.
Via Business Wire
Natera to Report Its Second Quarter Results on August 7, 2025
From Natera, Inc.
Via Business Wire
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
From Natera, Inc.
Via Business Wire
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades. 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
From Natera, Inc.
Via Business Wire
1 Growth Stock with Exciting Potential and 2 to Be Wary Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today
 
Via Benzinga
1 Volatile Stock to Own for Decades and 2 to Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Reasons We Love Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%. 
Via StockStory
Topics Government Stocks
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years
 
Via Benzinga
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue... 
Via StockStory
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses... 
Via StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
 
Via Benzinga
8 Analysts Have This To Say About Natera
 
Via Benzinga
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.